From fee for service to funding science
Multiple service providers have now launched their own venture funds or drug discovery arms. Are CDMOs/CROs the new Pharma?
FACILITATED BY
MAUREEN COLEMAN | Chair | CN BioInnovations
PANELLISTS INCLUDE
THOMAS OGORKA | Chief Executive Officer | Orphan Reach
JENNY LAIRD | Vice President, Search & Evaluation Pain & Neurodegeneration | Eli Lilly and Company
CHRISTOPHE MULLER | Global Head Business Development | Evotec
DECLAN JONES | Vice President and Head of External Innovation (EI) and Scientific Licensing | Ferring Research Institute
RICHARD WEAVER | Founder and Managing Director | XenoGesis
CHARLES STEWARD | Patient Advocacy and Engagement Lead | Congenica